

Resource Summary Report

Generated by [dkNET](#) on Sep 8, 2026

VAL

RRID:CVCL_1819

Type: Cell Line

Proper Citation

RRID:CVCL_1819

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1819

Proper Citation: RRID:CVCL_1819

Description: Cell line VAL is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Diffuse large B-cell lymphoma

Defining Citation: [PMID:8220427](#), [PMID:8558920](#), [PMID:16960149](#), [PMID:19358282](#), [PMID:20454443](#), [PMID:26727417](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31160637](#), [PMID:35839778](#)

Comments: Miscellaneous: Originally assigned to be from a B-cell acute lymphoblastic leukemia., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: VAL

Cross References: CLO:CLO_0037067, EFO:EFO_0022344, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioSample:SAMN03473489, cancercellines:CVCL_1819, Cell_Model_Passport:SIDM00416, Cosmic:1086346, Cosmic:1517631, Cosmic:1541908, Cosmic:2276320, Cosmic:2297002, Cosmic:2590022, Cosmic-CLP:1331048, DepMap:ACH-001703, DSMZ:ACC-586, DSMZCellDive:ACC-586, EGA:EGAS00001000978, GDSC:1331048, GEO:GSM115973, GEO:GSM201349,

GEO:GSM1035309, GEO:GSM1670570, LINCS_LDP:LCL-1915, Lonza:1237, PharmacDB:VAL_1652_2019, PRIDE:PXD030304, Progenetix:CVCL_1819, Wikidata:Q54992842

ID: CVCL_1819

Record Creation Time: 20220427T221707+0000

Record Last Update: 20260905T182719+0000

Ratings and Alerts

No rating or validation information has been found for VAL.

No alerts have been found for VAL.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Tang E, et al. (2026) Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy. Cancer immunology research, 14(8), 1292.

Mani R, et al. (2025) TP53 upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in BCL2-rearranged lymphomas. iScience, 28(6), 112584.

Chen Z, et al. (2025) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. Cell, 188(2), 331.

Mehdi SH, et al. (2024) Development of New Diffuse Large B Cell Lymphoma Mouse Models. Cancers, 16(17).

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications, 3(4), 576.

Parvin S, et al. (2019) LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL. Cancer cell, 36(3), 237.